List of Ixempra Kit drug patents
Ixempra Kit is owned by R-Pharm Us Llc.
Ixempra Kit contains Ixabepilone.
Ixempra Kit has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Ixempra Kit are:
- US7022330
- US6670384
- USRE41393
- US6670384*PED
- US7022330*PED
- USRE41393*PED
Ixempra Kit was authorised for market use on 16 October, 2007.
Ixempra Kit is available in injectable;intravenous dosage forms.
Ixempra Kit can be used as method of treating breast cancer by administering ixabepilone; a method of treating a cancer responsible to microtubule stabilization by administering ixabepilone, use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer, method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt, method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent; method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml.
The generics of Ixempra Kit are possible to be released after 21 February, 2025.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7022330 | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jan, 2022
(1 year, 1 month ago) | |
| US6670384 | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jan, 2022
(1 year, 1 month ago) | |
| USRE41393 | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Feb, 2022
(1 year, 1 month ago) | |
|
US6670384
(Pediatric) | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jul, 2022
(7 months ago) | |
|
US7022330
(Pediatric) | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jul, 2022
(7 months ago) | |
|
USRE41393
(Pediatric) | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Aug, 2022
(7 months ago) | |
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(1 year, 5 months from now) | |
|
US7312237
(Pediatric) | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Feb, 2025
(1 year, 11 months from now) | |
Drugs and Companies using IXABEPILONE ingredient
Market Authorisation Date: 16 October, 2007
Treatment: Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt; Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent; Method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; Lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml; Method of treating breast cancer by administering ixabepilone; A method of treating a cancer responsible to microtubule stabilization by administering ixabepilone; Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer
Dosage: INJECTABLE;INTRAVENOUS
IXEMPRA KIT family patents
25
United States
5
Norway
5
China
5
Canada
5
European Union
4
Russia
4
Brazil
4
Estonia
4
Mexico
4
Argentina
4
Korea, Republic of
4
South Africa
4
Slovakia
4
Japan
4
Bulgaria
4
Hungary
4
Czech Republic
4
Iceland
4
Poland
3
Uruguay
3
Croatia
3
Peru
3
Taiwan, Province of China
3
Hong Kong
3
Yugoslavia
3
Australia
2
Spain
2
New Zealand
2
Austria
1
Portugal
1
Germany
1
Cyprus
1
Slovenia
1
Israel
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic